Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81729 | 0.83 | EGFR (0.30) | EGFRPIK3CG | |
| SCHEMBL5336910 | 0.73 | EGFR (0.32) | EGFRPIK3CG | |
| SCHEMBL3931703 | 0.68 | — | — | |
| SCHEMBL3930826 | 0.68 | — | — | |
| SCHEMBL29355369 | 0.67 | EGFR (0.34) | EGFRPIK3CG | |
| SCHEMBL3292267 | 0.66 | PIK3CG (0.47) | EGFRPIK3CG | |
| Potassium SCHEMBL29619940 | 0.65 | EGFR (0.33) | EGFRPIK3CG | |
| Phosphine SCHEMBL3090397 | 0.65 | CHRNB4 (0.33) | EGFRPIK3CG | |
| Hydrogen Sulfide SCHEMBL29184284 | 0.65 | EGFR (0.33) | EGFRPIK3CG | |
| Hydrochloric Acid SCHEMBL27567069 | 0.65 | EGFR (0.33) | EGFRPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154941-B1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2021-01-20 | — | — | EP | claimed |
| US-10550203-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2020-02-04 | — | — | US | claimed |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | claimed |
| US-20180319905-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-11-08 | — | — | US | claimed |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ALLOCYTE PHARMACEUTICALS AG (CH) | 2018-09-18 | — | — | US | claimed |
| EP-2190790-B1 | INCREASE IN BIOCIDAL EFFECT OF HYDROGEN PEROXIDE IN WASTE WATERS BY TRANSITION METAL CATALYSTS | KURITA WATER IND LTD (JP) | 2017-06-21 | — | — | EP | claimed |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2017-05-04 | — | — | US | claimed |
| EP-3154941-A1 | SMALL MOLECULE LFA-1 INHIBITORS | AlloCyte Pharmaceuticals AG (CH) | 2017-04-19 | — | — | EP | claimed |
| US-20170015760-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2017-01-19 | — | — | US | claimed |
| US-9469741-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | claimed |
| WO-2001007048-A1 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-01 | — | — | WO | claimed |
| WO-2001007044-A1 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-01 | — | — | WO | claimed |
| WO-2001007052-A1 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-01 | — | — | WO | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| EP-0966447-A1 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1999-12-29 | — | — | EP | claimed |
| US-5955481-A | Pyridine type thiazolidines | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | claimed |
| WO-1998039303-A1 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1998-09-11 | — | — | WO | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| EP-0167820-B1 | PROCESS FOR THE PREPARATION OF OPTIONALLY SUBSTITUTED BENZ(C,D)-INDOL-2-ONES (NAPHTHOLACTAMES) | BAYER AG (DE) | 1989-04-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ICAM1, VCAM1, ITGB1 | EGFR 2481/4885PIK3CG 3186/4885 |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | EGFR 2481/4885PIK3CG 3186/4885 |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | EGFR 2481/4885PIK3CG 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.